JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB250407

Anti-C8G antibody [EPR11274] - BSA and Azide free

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal CO8G antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human samples. Cited in 1 publication.

View Alternative Names

Complement component C8 gamma chain, C8G

2 Images
Immunocytochemistry/ Immunofluorescence - Anti-C8G antibody [EPR11274] - BSA and Azide free (AB250407)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-C8G antibody [EPR11274] - BSA and Azide free (AB250407)

This data was developed using ab181182, the same antibody clone in a different buffer formulation.

Immunofluorescence analysis of Human SW480 cells, staining C8G (red) with ab181182 at 1/100 dilution. An Alexa Fluor®555-conjugated goat anti-rabbit IgG was used as a secondary antibody at 1/200 dilution. Nuclei were counterstained with DAPI (blue).

Western blot - Anti-C8G antibody [EPR11274] - BSA and Azide free (AB250407)
  • WB

Supplier Data

Western blot - Anti-C8G antibody [EPR11274] - BSA and Azide free (AB250407)

This data was developed using ab181182, the same antibody clone in a different buffer formulation.

All lanes:

Western blot - Anti-C8G antibody [EPR11274] - C-terminal (<a href='/en-us/products/primary-antibodies/c8g-antibody-epr11274-c-terminal-ab181182'>ab181182</a>) at 1/1000 dilution

Lane 1:

Human colon cancer lysate at 20 µg

Lane 2:

Human plasma at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 22 kDa

Observed band size: 22 kDa

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR11274

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

ICC/IF, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Complementary Products

Primary Antibodies

AB181190

Anti-Sacsin antibody [EPR11864]

RabMAb|Recombinant|Trial Size|Trial Size

Western blot - Anti-Sacsin antibody [EPR11864] (AB181190)

  • 0
  • 0
Primary Antibodies

AB133709

Anti-SAMM50/SAM50 antibody [EPR8718]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SAMM50/SAM50 antibody [EPR8718] (AB133709)

  • 5
  • 1
Primary Antibodies

AB195807

Anti-NDUFS6 antibody [EPR15957]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NDUFS6 antibody [EPR15957] (AB195807)

  • 0
  • 0
Primary Antibodies

AB181195

Anti-TTC4 antibody [EPR13381-76]

RabMAb|Recombinant|Trial Size|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TTC4 antibody [EPR13381-76] (AB181195)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" }, "Mouse": { "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rat": { "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }
style
left-column

Product details

ab250407 is the carrier-free version of ab181182.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C8G also known as complement component 8 gamma plays a significant role in the immune system's function. This protein has a mass of approximately 22 kDa and forms a part of the complement component 8 complex which acts as a critical player in the formation of the Membrane Attack Complex (MAC). Researchers have found C8G in various tissues with notable expression in the liver. The protein is generally released into the bloodstream as part of its involvement in immune responses.
Biological function summary

Complement component 8 gamma participates in puncturing pathogen cell membranes. It functions within the Membrane Attack Complex a structure important for antimicrobial activity. C8G partners with complement components C8 alpha and C8 beta to form the complete C8 complex which then associates with other complement proteins to facilitate membrane penetration. This activity highlights its role in protecting the host from infectious agents by disrupting pathogen integrity.

Pathways

C8G contributes critically to the complement cascade particularly within the terminal pathway. This pathway involves other complement proteins like C5b C6 and C7 coordinating to assemble the MAC which serves as a defense mechanism against microbial invasion. Consistently C8G shares functional relationships with these proteins reinforcing its participation in immune mediators.

C8G dysfunction associates with conditions like Complement Component 8 Deficiency which results in increased susceptibility to Neisseria infections. Moreover alterations in C8G can link to systemic lupus erythematosus an autoimmune disease where complement activation may become dysregulated. C8G's interactions with C8 alpha and C8 beta components remain important in these pathophysiological contexts potentially serving as targets for therapeutic interventions aimed at modulating complement activity.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed : 26841837, PubMed : 27052168, PubMed : 30552328). The MAC is initiated by proteolytic cleavage of C5 into complement C5b in response to the classical, alternative, lectin and GZMK complement pathways (PubMed : 30552328, PubMed : 39914456, PubMed : 39814882). The complement pathways consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed : 30552328). C8G, together with C8A and C8B, inserts into the target membrane, but does not form pores by itself (PubMed : 30552328). During MAC assembly, associates with C5b, C6 and C7 to form the C5b8 intermediate complex that inserts into the target membrane and traverses the bilayer increasing membrane rigidity (PubMed : 30552328, PubMed : 6833260).
See full target information C8G
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Evidence-based complementary and alternative medicine : eCAM 2022:7757833 PubMed36091585

2022

Esculentoside A Alleviates Intestinal Dysmotility in Ulcerative Colitis by Regulating HS/CSE and NO/nNOS Systems.

Applications

Unspecified application

Species

Unspecified reactive species

Ying Liu,Wenhua Wei,Shiwei Liang,Haicheng Fang,Jie Cao
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com